About Us
What we do
Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company developing novel immunotherapies that guide T cells to overcome chronic infectious diseases and autoimmunity.
Our Story
Our work at Barinthus Bio is focused on developing product candidates that guide the immune system to cure disease.
Barinthus Bio is an emerging leader in the research and development of antigen-specific immunotherapies that guide T cells to fight disease. We are building on a rich history of cutting-edge innovations by our scientific founders from leading institutions.
Barinthus Bio arose from the merger of Oxford University spinout Vaccitech, Plc and National Institutes of Health (NIH) and Johns Hopkins University spinout, Avidea Technologies, Inc. in 2021. Joining two leading immunotherapeutics companies with complementary technologies and expertise has created powerful synergies, fueling innovation and a focused pipeline of promising product candidates.
Our Team
The foundation of Barinthus Bio is an experienced management team covering all stages of immunotherapeutics research and development from discovery through late stages of clinical development. Our team is unified by our values and driven by our mission of developing immunotherapies to improve the lives of patients
Our Name
Barinthus was the name of the mythological navigator who guided the legendary King Arthur of Britain by ship to the island of Avalon to be healed after he was wounded. Like Barinthus, our company aims to be a strong and resilient navigator, guiding T cells to cure disease. Our vessel is the power of science and our expertise harnesses it in directing the immune system to help people overcome chronic infectious diseases and autoimmunity.